Page 626 - Read Online

Ichida et al. Hepatoma Res 2020;6:54 I http://dx.doi.org/10.20517/2394-5079.2020.59 Page 11 of 11

Hepatobiliary Pancreat Sci 2017;24:49-57.
20. Nakao K, Ichikawa T. Recent topics on alpha-fetoprotein. Hepatol Res 2013;43:820-5.
21. Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, et al. Prediction of hepatocellular carcinoma biological behavior in
patient selection for liver transplantation. World J Gastroenterol 2016;22:232-52.
22. Kobayashi T, Aikata H, Honda F, Nakano N, Nakamura Y, et al. Preoperative fluorine 18 fluorodeoxyglucose positron emission
tomography/computed tomography for prediction of microvascular invasion in small hepatocellular carcinoma. J Comput Assist Tomogr
2016;40:524-30.
23. Imura S, Teraoku H, Yoshikawa M, Ishikawa D, Yamada S, et al. Potential predictive factors for microvascular invasion in hepatocellylar
carcinoma classified within the Milan criteria. Int J Clin Oncol 2018;23:98-103.
24. Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, et al. Expanded living-donor liver transplantation criteria for patients with
hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study. Transpl Int 2019;32:356-68.
25. Kokudo N, Sugawara Y, Imamura H, Sano K, Makuuchi M. Tailoring the type of donor hepatectomy for adult living donor liver
transplantation. Am J Transplant 2005;5:1694-703.
26. Akamatsu N, Sugawara Y, Kaneko J, Arita J, Sakamoto Y, et al. Low platelet counts and prolonged prothrombin time early after operation
predict the 90 days morbidity and mortality in living-donor liver transplantation. Ann Surg 2017;265:166-72.
27. Furukawa H, Shimamura T, Suzuki T, Taniguchi M, Nakanishi K, et al. Liver transplantation for hepatocellular carcinoma: the Japanese
experience. J Hepatobiliary Pancreat Sci 2010;17:533-8.
28. Tamura S, Sugawara Y, Kokudo N. Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience. Oncology
2011;81:111-5.
29. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, et al. Recommendations for liver transplantation for hepatocellular carcinoma:
an international consensus conference report. Lancet Oncol 2012;13:e11-22.
30. Todo S, Furukawa H, Tada M. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl
2007;13:S48-54.
31. Mailey B, Artinyan A, Khalili J, Denitz J, Sanchez-Luege N, et al. Evaluation of absolute serum α-fetoprotein levels in liver transplant for
hepatocellular cancer. Arch Surg 2011;146:26-33.
32. Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular
carcinoma. Liver Transpl 2013;19:634-45.
33. Zheng SS, Xu X, Wu J, Chen J, Wang WL, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.
Transplantation 2008;85:1726-32.
34. Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R, Addissie BD, Mohamed EA, et al. Model combining pre-transplant tumor
biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models.
World J Gastroenterol 2018;24:1321-31.
35. Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, et al. Clinical advantage of highly sensitive on-chip immunessay for fucosylated
fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci 2010;55:3576-83.
36. Hanaoka T, Sato S, Tobita H, Miyake T, Ishihara S, et al. Clinical significance of the highly seisitive fucosylated fraction of alpha-
fetoprotein in patients with chronic liver disease. J Gastroenterol Hepatol 2011;26:739-44.
37. Toyoda H, Kumada T, Tada T. Highly sensitive Lens clinaris agglutinin-reactive alpha-fetoprotein: a new tool for the management of
hepatocellular carcinoma. Oncology 2011;81:61-5.
38. Olthoff KM, Goldberg DS. The MoRAL path beyond Milan. Ann Surg 2016;263:851-2.
39. Shirabe K, Itoh S, Yoshizumi T, Soejima Y, Taketomi A, et al. The predictors of microvascular invasion in candidates for liver
transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg
Oncol 2007;95:235-40.
40. Rosenblatt RE, Tafesh ZH, Halazun KJ. Role of inflamematory markers as hepatocellular cancer selection tool in the setting of liver
transplantation. Transl Gastroenterol Heaptol 2017;2:95.
41. Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver
transplantation. World J Hepatol 2019;11:50-64.
42. Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, et al. Recurrence after liver transplantation for hepatocellular
carcinoma: a new MORAL to the story. Ann Surg 2017;265:557-64.
43. Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, et al. Liver transplantation in hepatocellular carcinoma after tumour
downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020;21:947-56.